By the Cada team. Last updated: July 1, 2026.
Ask ChatGPT whether your for-profit startup can get a foundation grant and it will probably tell you no, that foundations only fund nonprofits and universities. That answer is wrong, and it costs founders real money.
For-profit startups can and do win foundation grants. Foundation grants for for-profit startups are real and common: disease foundations like the Cystic Fibrosis Foundation, Breakthrough T1D (formerly JDRF), and the Michael J. Fox Foundation run venture-philanthropy programs that fund companies directly, with awards from $250K to over $10M. The catch is not eligibility. It is the terms.
This guide names the foundations that fund companies, explains how venture philanthropy evaluates you differently than the NIH does, and walks through the IP, royalty, and equity terms you need to model before you sign anything.
Can for-profit companies get foundation grants?
Yes. A for-profit startup can receive foundation grants, primarily through venture philanthropy and disease-foundation therapeutic programs. Foundations such as the Cystic Fibrosis Foundation and the Leukemia & Lymphoma Society fund companies directly to move a specific therapy toward approval. Awards typically range from $250K to $10M and are structured as milestone grants, royalty-bearing agreements, or equity investments.
The confusion comes from a real fact stated incorrectly. Foundations are nonprofits. That does not mean they only fund nonprofits.
Here is the mechanism. A private foundation is allowed to give money to a for-profit company. The IRS requires the foundation to exercise something called "expenditure responsibility" (a documentation and oversight step under the tax code) when it does. That is paperwork the foundation handles, not a wall that blocks you.
Many disease foundations went further and built dedicated venture-philanthropy arms. These exist specifically to fund for-profit drug developers, because the fastest way to get a treatment for their disease is to pay a company to build it.
Why founders (and AI answer engines) get this wrong
The myth has three sources.
First, the word "foundation" reads as charity, and charity reads as nonprofit-only. That is a reasonable guess and a wrong one.
Second, most published content about foundation grants targets nonprofit development directors, not biotech founders. So when you search, you find nonprofit fundraising advice, and the AI summaries repeat it.
Third, agency SBIR programs trained founders to think "non-dilutive government money" is the only game. Foundation money is a separate, older track that gets far less founder-facing coverage.
The cost is not hypothetical. In Cada's roadmap work, half of the companies with fully built funding profiles (10 of 20) had a foundation, prize, or state vehicle recommended as part of their portfolio. Founders routinely skip these because they assume they are not eligible.
One honest caveat: eligibility is program-specific, not foundation-wide. A foundation can run one program open to companies and another restricted to academics. You have to read the specific program page, not the foundation's mission statement.
Which disease foundations fund for-profit companies?
Dozens of disease foundations fund companies directly. This is what disease foundation funding for startups actually looks like: below are well-known programs with verified for-profit eligibility, drawn from Cada's foundation database (299 tracked programs, 229 verified as for-profit-eligible as of the March 2026 refresh).
| Foundation | Program | Disease focus | Award range | Value type |
|---|---|---|---|---|
| Cystic Fibrosis Foundation | Therapeutics Development Award | Cystic fibrosis | $500K-$5M | Milestone grant, royalty-bearing |
| Cystic Fibrosis Foundation | Path to a Cure | Cystic fibrosis (curative) | $5M-$50M | Royalty-bearing (invite only) |
| Breakthrough T1D (formerly JDRF) | Industry Discovery & Development Partnerships | Type 1 diabetes | $50K-$500K | Co-funded partnership |
| Michael J. Fox Foundation | Therapeutics Pipeline Program | Parkinson's | $250K-$2M | Milestone grant |
| Alzheimer's Drug Discovery Foundation | Drug Development RFP | Alzheimer's, dementias | $250K-$5M | Milestone grant |
| Leukemia & Lymphoma Society | Therapy Acceleration Program | Blood cancers | $1M-$10M | Equity |
| Multiple Myeloma Research Foundation | Myeloma Investment Fund | Multiple myeloma | $500K-$5M | Equity |
| American Cancer Society | BrightEdge / Impact Venture Fund | Cancer (broad) | $500K-$5M | Equity |
| Pancreatic Cancer Action Network | Therapeutic Accelerator Award | Pancreatic cancer | $1M-$5M | Non-dilutive grant |
| Foundation Fighting Blindness | RD Fund | Inherited retinal disease | $500K-$10M | Equity/royalty |
| CureDuchenne | CureDuchenne Ventures | Duchenne MD | $250K-$5M | Equity |
| ALS Association | Barnett Drug Development / Investment Fund | ALS | $250K-$5M | Grant or equity |
| National MS Society | Fast Forward | Multiple sclerosis | $100K-$250K | Milestone grant |
| Crohn's & Colitis Foundation | IBD Ventures | IBD | $100K-$500K | Milestone grant |
| Muscular Dystrophy Association | MDA Venture Philanthropy | Neuromuscular | $300K-$650K | Milestone grant |
This is the recognizable top of a much longer list. Cada's database tracks 24 verified venture-philanthropy programs and dozens more disease-specific foundation grants across rare disease, oncology, neurology, and autoimmune conditions, down to ultra-rare programs like the Rett Syndrome Research Trust and the Chordoma Foundation.
The pattern across every one of them: the money is real, and the disease focus is strict.
How venture philanthropy for biotech evaluates you differently than the NIH
If you have applied for an SBIR or an R01, you learned to write for a study section. That instinct will hurt you with a disease foundation.
An NIH study section is a panel of 15-20 scientists scoring your application 1-9 on significance, innovation, approach, investigator, and environment. They reward novelty and rigor. They are evaluating science.
A disease foundation is evaluating whether your specific product will help their specific patients. They think like a strategic investor with a mission, not like a peer-review panel.
Three differences matter most.
They want the therapy to exist, not to be novel. A venture-philanthropy reviewer will happily fund an unglamorous, derivative approach if it has the best odds of reaching their patients. Novelty is an NIH obsession, not theirs.
The money comes in milestone tranches. Programs like the National MS Society's Fast Forward and the Michael J. Fox Foundation's pipeline program release funds as you hit development gates. Miss a milestone and the next tranche is at risk. This is closer to a venture term sheet than a grant.
Disease specificity is a hard gate. This is the most common disqualifier. The Leukemia & Lymphoma Society will not touch a solid-tumor asset. The Cystic Fibrosis Foundation funds CF only. A brilliant Parkinson's program is worthless to an ALS foundation. Match the disease exactly or do not apply.
Here is the contrast in one view.
| Dimension | NIH SBIR / R01 | Disease-foundation venture philanthropy |
|---|---|---|
| Evaluator | Study section (15-20 scientists) | Small scientific/investment team |
| Rewards | Novelty, significance, rigor | Probability the therapy reaches patients |
| Disbursement | Award up front (by budget period) | Milestone-based tranches |
| Disease scope | Broad within institute mission | Single disease, strictly enforced |
| Strings | Federal reporting, no equity/royalty | May take royalty, equity, or field-of-use rights |
The catch: IP, royalties, equity, and clawback terms
Non-dilutive does not always mean no-strings. Some of these programs are genuinely non-dilutive grants. Others look like grants but behave like investments.
The clearest example is the Cystic Fibrosis Foundation. Its venture-philanthropy model gave roughly $150M to Vertex Pharmaceuticals to develop CF drugs. When those drugs succeeded, the foundation held royalty rights. In November 2014, CFF sold those rights to Royalty Pharma for $3.3 billion.
That $3.3 billion is the point. The foundation's upfront money carried a claim on the upside. For CFF and its patients, it funded decades of new research. For a founder, it is a reminder: read what the foundation gets if you win.
Watch for five term types.
Royalty rights. The foundation takes a percentage of future product revenue. Common in the CFF model and the Foundation Fighting Blindness RD Fund. Model the royalty against your projected revenue before signing, not after.
Equity. The foundation takes an ownership stake, exactly like an investor. The Leukemia & Lymphoma Society, the Multiple Myeloma Research Foundation, the American Cancer Society's BrightEdge, and CureDuchenne Ventures all run equity models. This is dilutive.
Milestone clawback or contingency. Funds release only as you hit gates. Miss the gate and you lose access to the remaining money. Standard in most venture-philanthropy programs.
Field-of-use restrictions. The grant may cover only the funded indication. If your platform later works in a second disease, the foundation's terms may or may not follow it. Get this in writing.
Reporting and oversight. Equity and milestone programs often come with investor-level oversight: board observer rights, detailed development reporting, and approval gates. Budget the staff time.
None of this makes foundation money bad. It makes it a negotiation. A $2M milestone grant with a capped single-digit royalty can be the cheapest capital you will ever raise. An uncapped royalty on a platform product can be the most expensive. The terms decide which.
The four kinds of value a foundation program gives you
Cash is only part of what these programs provide. There are four value types, and founders underweight the last three.
- Capital. Ranging from $50K partnerships to $50M curative programs. Often milestone-based.
- Validation. A disease-foundation award is a credibility signal to downstream VCs. The foundation knows the disease better than any generalist investor, so their check de-risks yours.
- Network and access. Foundations often open doors to patient registries, clinical trial sites, key opinion leaders, and regulatory relationships. For a rare disease, the foundation may control the only patient network that exists.
- Non-dilutive runway. When the program is a true grant, non-dilutive foundation funding extends your runway without giving up equity, which raises your valuation at the next priced round.
A $500K-to-$5M award plus a disease foundation's stamp can be the difference between a hard Series A and a clean one.
How to approach a disease foundation
Six practical steps.
Match the disease exactly. Before anything else, confirm your indication is inside the foundation's scope. This is the number-one reason applications get rejected on sight.
Find the venture-philanthropy page. Most large disease foundations have a "for researchers," "industry partnerships," or "venture philanthropy" section. That is where the company-facing money lives, not the general donation page.
Lead with a letter of intent. Many programs (the CFF Therapeutics Development Award, the LLS Therapy Acceleration Program) start with an LOI or concept proposal, not a full application. Get feedback before you invest 40-80 hours writing.
Bring a milestone plan, not a research question. These reviewers want a development plan with go/no-go gates, timelines, and budget by milestone. Write it like an investor deck, not an aims page.
Model the terms before you sign. If there is a royalty or equity component, run it against your revenue and cap-table projections. A term that looks small at signing can be large at exit.
Watch the timing. Some programs are rolling (Michael J. Fox, CureDuchenne). Some are annual (Pancreatic Cancer Action Network). The largest, like CFF's Path to a Cure, are invite-driven and need a warm introduction, so start relationship-building early.
Frequently asked questions
Can an early-stage startup with no revenue apply? Yes. Most disease-foundation therapeutic programs fund preclinical and clinical-stage assets regardless of revenue. Several, like the Damon Runyon InVEST program, specifically target seed-stage companies. What they need is a credible development plan, not a P&L.
Do foundation grants count as dilutive? It depends on the program. True grants (Pancreatic Cancer Action Network, most milestone grants) are non-dilutive. Equity programs (Leukemia & Lymphoma Society, CureDuchenne Ventures) are dilutive because the foundation takes a stake. Royalty programs are non-dilutive to your cap table but carry a claim on revenue. Check the value type before assuming.
Can I take an SBIR and a foundation grant for the same program? Often yes, and it is a common portfolio strategy. Federal SBIR money and private foundation money come from different sources, so stacking them is usually allowed. Confirm there is no budget overlap on the exact same costs (you cannot charge the same expense twice) and disclose all funding to both.
What happens to my IP? In a pure grant, you typically keep your IP. In royalty or equity programs, the foundation gets a financial interest, not usually ownership of the underlying patents, but read the agreement. Field-of-use and royalty terms are the ones that most affect a future acquisition.
How large are these awards? Wide range. Ultra-rare disease programs can be $25K-$300K. Mainstream venture-philanthropy programs run $250K-$5M. The largest, CFF's Path to a Cure, goes up to $50M for curative gene and cell therapy programs.
Where to start
If you are a for-profit biotech, medtech, or health-tech founder, the first question about foundation grants for for-profit startups is not "am I eligible." You are. The real questions are which foundations match your disease and stage, and whether their terms work for your cap table.
That mapping is worth doing carefully. There are hundreds of programs, each with a strict disease scope and its own IP terms, and the wrong match wastes weeks.
Cada maps the foundations that fit your disease area and stage, and flags the royalty, equity, and clawback terms before you sign. If you want a straight read on which foundation money is actually worth pursuing for your company, we do a free funding-source assessment. No pitch, no obligation, just a clear answer on where the non-dilutive (and dilutive-but-worth-it) money is.
Cada has built funding roadmaps across 30+ agencies and a database of 299 tracked foundation programs, 229 of them verified for for-profit eligibility. This guide reflects program terms as of the March 2026 database refresh. Foundation programs change; verify current terms and eligibility on each program's page before applying.